Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Iridocorneal endothelial (ICE) syndrome describes a group of progressive corneal proliferative endotheliopathies comprised of Chandler syndrome, Cogan-Reese syndrome and essential iris atrophy, affecting mainly young adult females and characterized by iris holes and atrophy, papillary distortion, anterior synechiae, corneal edema and often with secondary glaucoma and corneal decompensation as complications
Biomarker and diagnostic research for iridocorneal endothelial syndrome has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for iridocorneal endothelial syndrome.
25 publications have been identified in PubMed for iridocorneal endothelial syndrome. Research spans Case Report / Case Series (28%), Clinical Trial Publication (28%), and Review / Meta-Analysis (16%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 7 | 28% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 9:41 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Clinical study results
7 |
28% |
Research summaries | 4 | 16% |
Other research | 3 | 12% |
Laboratory research | 2 | 8% |
Testing and diagnosis research | 1 | 4% |
Disease patterns and progression | 1 | 4% |
Golschan E (2026). [PMID: 41540121](https://pubmed.ncbi.nlm.nih.gov/41540121/). *Ophthalmologie*. [Clinical Trial Publication]
Price MO (2026). [PMID: 39774564](https://pubmed.ncbi.nlm.nih.gov/39774564/). *Cornea*. [Clinical Trial Publication]
Das S (2026). [PMID: 37603618](https://pubmed.ncbi.nlm.nih.gov/37603618/). *Unknown Journal*. [Other]
Kaur K (2026). [PMID: 36256774](https://pubmed.ncbi.nlm.nih.gov/36256774/). *Unknown Journal*. [Diagnostic / Biomarker]
Borodi PG (2026). [PMID: 42146950](https://pubmed.ncbi.nlm.nih.gov/42146950/). *Rom J Ophthalmol*. [Case Report / Case Series]
Zhang J (2026). [PMID: 40526465](https://pubmed.ncbi.nlm.nih.gov/40526465/). *Cornea*. [Basic Science / Preclinical]
Ma H (2025). [PMID: 41127405](https://pubmed.ncbi.nlm.nih.gov/41127405/). *Front Ophthalmol (Lausanne)*. [Review / Meta-Analysis]
Leong EYX (2025). [PMID: 40868931](https://pubmed.ncbi.nlm.nih.gov/40868931/). *Life (Basel)*. [Review / Meta-Analysis]
Murra S (2025). [PMID: 41474960](https://pubmed.ncbi.nlm.nih.gov/41474960/). *Cornea*. [Epidemiology / Natural History]
Shah A (2025). [PMID: 41043826](https://pubmed.ncbi.nlm.nih.gov/41043826/). *BMJ Case Rep*. [Case Report / Case Series]
AI-curated news mentioning iridocorneal endothelial syndrome
Updated Sep 3, 2026
A contemporary review highlights the pathogenesis, multimodal diagnosis, and management strategies for iridocorneal endothelial syndrome. This comprehensive analysis provides insights into the disease's complexities and potential therapeutic approaches.